Magnesium for Migraines

Magnesium is one of the very few over-the-counter supplements with formal guideline-level evidence for migraine prevention. The American Academy of Neurology and the American Headache Society jointly classify oral magnesium as Level B (probably effective) for migraine prophylaxis — the same evidence tier as butterbur, riboflavin, and feverfew, and just one step below the prescription preventives (Level A). The clinical story has three pillars: Alexander Mauskop's decades of work on serum and intracellular magnesium deficiency in migraine patients, randomized trials of 600 mg/day oral magnesium for prevention, and the emergency-department use of IV magnesium sulfate (1-2 g) for acute migraine, particularly migraine with aura. The mechanism is the elegant convergence of NMDA receptor blockade (the same gating receptor that initiates cortical spreading depression), serotonin and CGRP modulation, vascular tone regulation, and platelet aggregation inhibition. This deep-dive walks through the evidence base, the practical dosing, the pediatric trials, and the role of menstrual-cycle magnesium drop in catamenial migraine.

The Mauskop Body of Work
Mechanism — NMDA, CGRP, Serotonin, Cortical Spreading Depression
Oral Magnesium for Migraine Prophylaxis
The American Academy of Neurology Level B Rating
IV Magnesium for Acute Migraine in the ED
Bigal and the Aura Subgroup
Pediatric Migraine Trials
Menstrual Migraine and the Late-Luteal Magnesium Drop
Forms and Dosing for Migraine Prevention
Combining Magnesium with Riboflavin, CoQ10, and Feverfew
Cautions, Side Effects, and Drug Interactions
Key Research Papers
Connections

The Mauskop Body of Work

Alexander Mauskop, founding director of the New York Headache Center, has been the most consistent academic voice for magnesium in migraine for more than three decades. His 2012 review with Varughese in Journal of Neural Transmission, titled "Why all migraine patients should be treated with magnesium," remains the most-cited single article on the topic and is the polite-but-pointed clinical position paper for routine prophylactic use.

The Mauskop research program has documented three distinct findings:

Magnesium deficiency is common in migraine patients — Up to 50% of migraineurs have low ionized magnesium during an acute attack, even when serum total magnesium is in the normal range. The dissociation between serum total and serum ionized magnesium is itself diagnostic of intracellular deficiency in a subset of migraine sufferers.
IV magnesium aborts acute attacks — In a landmark open-label series, Mauskop's group documented that IV magnesium sulfate 1 g produced complete relief or significant improvement in 80% of patients with low ionized magnesium, and in a smaller but still meaningful fraction of patients with normal ionized magnesium. The effect was typically within 15 minutes and durable for at least 24 hours in many patients.
Oral magnesium reduces attack frequency — Long-term oral supplementation at 400-600 mg/day reduced migraine frequency by approximately 40-50% in his clinical population, consistent with subsequent RCTs.

The Mauskop framework underpins the modern argument that any migraine patient who fails first-line management with avoidance of triggers and acute medications should be tried on prophylactic magnesium before moving to prescription preventives such as topiramate, propranolol, or CGRP antagonists. The risk-benefit ratio — cheap, well-tolerated, no abuse potential, no rebound — is uniquely favorable.

Back to Table of Contents

Mechanism — NMDA, CGRP, Serotonin, Cortical Spreading Depression

Migraine is not a single disease but a syndrome that emerges from interlocking neurological, vascular, and inflammatory processes. Magnesium intervenes at multiple steps, which is part of why it works across migraine subtypes (with or without aura, menstrual, pediatric, chronic) and why it complements rather than competes with prescription preventives.

NMDA receptor blockade — Magnesium is the endogenous voltage-dependent blocker of the NMDA glutamate receptor. NMDA hyperactivity is the central event in cortical spreading depression — the slow wave of cortical depolarization followed by sustained suppression that propagates across the visual cortex during a typical migraine with aura. Adequate magnesium raises the threshold for cortical spreading depression and reduces the likelihood that an attack initiates. This is the single most parsimonious mechanistic explanation for migraine prophylaxis.
CGRP modulation — Calcitonin gene-related peptide (CGRP) is the dominant neuropeptide released by trigeminal sensory afferents during a migraine attack; CGRP causes vasodilation of meningeal blood vessels and sensitization of trigeminal pain pathways. The recent class of anti-CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab) has revolutionized migraine prevention. Magnesium dampens CGRP release at lower physiological doses, supplying part of the mechanism by which magnesium reduces attack frequency.
Serotonergic tone — Migraine is intimately linked to dysregulated serotonin signaling; the triptan class of acute medications targets serotonin 5-HT1B/1D receptors. Magnesium is a cofactor in the tryptophan-to-serotonin synthesis pathway, supports serotonin receptor function, and may indirectly stabilize the serotonergic tone that triggers attacks during letdown from stress or hormonal change.
Platelet aggregation — Magnesium inhibits excessive platelet aggregation. Migraine, particularly migraine with aura, is associated with platelet hyperactivity and a small but real elevated risk of ischemic stroke. The platelet effect of magnesium provides a secondary protective mechanism.
Vascular tone — The vascular component of migraine (the throbbing quality, the photophobia mediated by vascular pulsation) involves dysregulated cranial vasomotor control. Magnesium's direct vasodilatory effect on small arteries and its calcium-channel-blocker-like action reduce the abnormal vasoconstriction-vasodilation cycles thought to contribute to the pain phase.
Cellular energy — Migraine cortices show reduced ATP and phosphocreatine on phosphorus MR spectroscopy — a kind of cortical energy-failure signature. Magnesium-ATP is the active form of cellular energy currency; magnesium repletion may improve cortical energy reserves and reduce the susceptibility to spreading depression.

The convergence of mechanisms is striking. Magnesium hits NMDA, CGRP, serotonin, platelets, vascular tone, and ATP metabolism simultaneously. Each individual effect is modest; together they produce the consistent ~40-50% reduction in attack frequency seen in well-conducted oral magnesium trials.

Back to Table of Contents

Oral Magnesium for Migraine Prophylaxis

Three randomized controlled trials anchor the prophylactic evidence base:

Peikert, Wilimzig, Köhne-Volland (1996, Cephalalgia) — A 12-week double-blind RCT in 81 patients with migraine without aura, randomized to 600 mg/day trimagnesium dicitrate vs. placebo. Attack frequency dropped by 41% in the magnesium group vs. 15% in placebo (p = 0.05). Migraine days and total intake of acute medications also fell. This is the most widely cited oral magnesium prophylaxis trial and the basis for the AAN/AHS Level B recommendation.
Pfaffenrath et al. (1996, Cephalalgia) — A larger (n = 150) but methodologically more complex trial using a different magnesium formulation (10 mmol BID = ~485 mg elemental daily) failed to show a statistically significant primary endpoint, though there was a trend toward benefit. The negative result is generally attributed to a less bioavailable formulation and unusually high placebo response.
Köseoglu et al. (2008, Magnesium Research) — A 12-week RCT in 40 patients with migraine without aura at 600 mg/day magnesium citrate vs. placebo. Significant reductions in attack frequency, severity, and the cortical perfusion abnormalities visualized on SPECT scanning.

Pooled across the prophylactic literature, oral magnesium at 400-600 mg/day reduces migraine frequency by approximately 40%, with the effect typically reaching steady state at 8-12 weeks. The number needed to treat (NNT) for a 50% reduction in attack frequency is approximately 3-4, which compares favorably with prescription preventives and is uniquely favorable on the side-effect side.

Back to Table of Contents

The American Academy of Neurology Level B Rating

The 2012 joint guideline from the American Academy of Neurology (AAN) and the American Headache Society (AHS) on episodic migraine prevention (Holland et al., Neurology) explicitly classified magnesium as Level B evidence (probably effective; should be considered for migraine prevention).

The Level B grouping in the 2012 guideline included:

Magnesium — 600 mg/day trimagnesium dicitrate
Riboflavin (Vitamin B2) — 400 mg/day
Feverfew (MIG-99) — 50-300 mg/day standardized extract
Histamine — 1-10 ng subcutaneously twice weekly

For comparison, the Level A grouping (established effective) included divalproex sodium, sodium valproate, topiramate, metoprolol, propranolol, timolol, and frovatriptan (for short-term menstrual migraine prevention). Petasites (butterbur) was originally Level A but was downgraded following hepatotoxicity concerns.

The practical implication is that any clinician treating migraine prophylactically has access to a guideline-endorsed, low-cost, well-tolerated, OTC option that can be tried before or alongside prescription preventives. The 2021 AHS consensus update reinforced this and explicitly recommended magnesium as a first-line option in patients with episodic migraine who prefer non-pharmacological or low-pharmacological approaches.

Back to Table of Contents

IV Magnesium for Acute Migraine in the ED

For acute migraine refractory to standard ED management (NSAIDs, antiemetics, triptans, DHE), IV magnesium sulfate has emerged as a useful adjunct, particularly in the subset with migraine with aura or in patients who cannot tolerate triptans (pregnancy, vascular contraindications).

Standard ED regimen — Magnesium sulfate 1-2 g IV over 15-20 minutes. Onset of pain relief is typically within 15-30 minutes; durability is 24 hours or longer in responders. The infusion is generally well tolerated; the main side effect is a sensation of warmth or flushing, occasional hypotension if given too rapidly.
Bigal et al. (2002, Cephalalgia) — A double-blind RCT in 60 patients with acute migraine in the ED randomized to 1 g IV magnesium sulfate vs. placebo. In the subgroup with aura, magnesium produced significantly greater pain reduction than placebo. In the subgroup without aura, the difference was not statistically significant. This is the trial most often cited as evidence for the aura-specific benefit.
Chiu et al. (2016, Pain Physician) — A meta-analysis of 21 trials of IV and oral magnesium for migraine concluded that IV magnesium significantly reduced acute migraine intensity in randomized trials, with effect sizes comparable to standard ED therapies. Oral magnesium reduced frequency and intensity of attacks in prophylaxis.
Use in pregnancy — IV magnesium has an established safety record in pregnancy (it is the standard of care for preeclampsia seizure prophylaxis), making it a useful option for acute migraine in pregnant women, who have few alternatives.
Status migrainosus — In status migrainosus (migraine lasting more than 72 hours) IV magnesium is one of the regimens trialed before more aggressive interventions such as DHE infusion, IV corticosteroids, or admission for inpatient pain management.

Back to Table of Contents

Bigal and the Aura Subgroup

The Bigal trial deserves a closer look because it shaped the modern view that magnesium is particularly effective in migraine with aura, the subtype where cortical spreading depression is the mechanistic centerpiece. The aura phase — typically visual scintillations, scotomas, or paresthesias — is the clinical correlate of cortical spreading depression spreading at ~3 mm/min across the occipital and parietal cortex. NMDA receptor activation is required for cortical spreading depression to propagate; magnesium blockade of NMDA raises the threshold.

The clinical pattern — Patients with migraine with aura who receive IV magnesium in the ED frequently report not only pain relief but resolution of any ongoing aura symptoms. The mechanistic match (NMDA blockade halting the spreading wave) is direct.
Implications for oral prophylaxis — Patients with frequent migraine with aura are the highest-yield candidates for oral magnesium prophylaxis. The CGRP-antibody trials excluded patients with hemiplegic migraine but included migraine with aura, and the aura subgroup tends to respond well to magnesium, suggesting that combining the two when needed is rational.
Magnesium and stroke risk — Migraine with aura carries a small but real increased risk of ischemic stroke, particularly in younger women and in those using estrogen-containing oral contraceptives. Magnesium's platelet-aggregation-inhibiting and vasculo-protective effects may offer secondary benefit beyond migraine control in this population.

Back to Table of Contents

Pediatric Migraine Trials

Pediatric migraine affects an estimated 8-10% of school-age children and 15-20% of adolescents, and parents and pediatricians are appropriately cautious about prescription preventives in this population. Magnesium has been studied specifically in pediatric migraine and is one of the few options with positive pediatric trial data.

Wang et al. (2003, Headache) — A randomized trial in 86 children and adolescents with frequent migraine, treated with magnesium oxide 9 mg/kg/day divided TID for 16 weeks. The magnesium group had significantly fewer headache days than the placebo group, with a trend toward reduced severity.
Practical pediatric regimen — The American Headache Society guidance for pediatric migraine prevention includes magnesium as a reasonable nonprescription first-line option, particularly in families seeking nonpharmacological management or in children with confirmed low magnesium intake. Typical dosing is 5-9 mg/kg/day elemental magnesium, divided.
Tolerability — Children tolerate magnesium glycinate well; magnesium oxide carries the same laxative caveat as in adults, particularly at higher pediatric doses. Glycinate or citrate is preferred in pediatric use.
Combined nutraceutical regimens — Many pediatric headache clinics use the "3-2-1" or similar combinations of magnesium, riboflavin, and CoQ10, which are individually Level B/C for adult migraine and reasonable to extrapolate to pediatrics in the absence of contraindications.

Back to Table of Contents

Menstrual Migraine and the Late-Luteal Magnesium Drop

Menstrually-related migraine is one of the best-characterized hormonal migraine subtypes. The attacks cluster in the two days before menses and the first three days of menstrual flow — the perimenstrual window. The most consistent biochemical correlate is the late-luteal drop in serum estradiol, but a parallel drop in serum magnesium has been documented and provides an additional mechanistic handle.

The luteal magnesium drop — Serum magnesium falls in the late luteal phase of the menstrual cycle, particularly in women with PMS and menstrual migraine. The mechanism is not fully established but appears to involve increased renal magnesium excretion and intracellular shifts driven by hormonal changes.
Facchinetti et al. (1991, Headache) — Demonstrated that women with menstrual migraine had lower intracellular magnesium and that oral magnesium 360 mg/day from day 15 of one cycle through the start of the next reduced the duration and intensity of menstrual migraine attacks.
Practical regimen — For menstrually-related migraine, options include: daily magnesium 400-600 mg/day year-round, or perimenstrual escalation from a baseline of 200-300 mg/day to 400-500 mg/day starting day 15-18 of the cycle. The perimenstrual escalation approach is particularly useful in women who don't need year-round prophylaxis but have predictable monthly attacks.
Combination approaches — Magnesium can be combined with continuous estrogen replacement (for women in whom hormonal management is the primary strategy), with frovatriptan short-term prevention (the AAN Level A short-term menstrual migraine intervention), or with triptans/NSAIDs for acute attacks.
Premenstrual syndrome overlap — Magnesium 200-360 mg/day (often combined with vitamin B6 50-100 mg) reduces PMS mood and physical symptoms, making it doubly attractive in women with PMS plus menstrual migraine.

Back to Table of Contents

Forms and Dosing for Migraine Prevention

Standard prophylactic dose — 400-600 mg elemental magnesium daily. The successful Peikert trial used 600 mg/day trimagnesium dicitrate (which delivers roughly 600 mg elemental in a citrate matrix); subsequent trials and clinical practice have shown that 400-600 mg/day is the responsive window.
Magnesium glycinate — Best tolerated, minimal GI effect, can be sustained at therapeutic doses (400-500 mg elemental) for months without diarrhea. The default first choice for migraine prevention.
Magnesium citrate — The form used in the Peikert trial. Good bioavailability, cheap, but mildly laxative at high doses; split AM/PM dosing improves tolerability.
Magnesium L-threonate — CNS-penetrating; theoretically the most rational form for a primarily central-nervous-system disease. Limited migraine-specific trial data but mechanistically elegant. Higher cost.
Magnesium oxide — Used in the Wang pediatric trial; cheap and high-elemental-content per gram of compound, but poorly absorbed at low GI tolerance. Reserve for cost-constrained pediatric use, otherwise prefer glycinate or citrate.
Loading period — Expect 8-12 weeks of consistent dosing before peak response. The Peikert trial showed continued improvement through week 12. Don't abandon at week 4 if response is modest.
Combination acute therapy — Oral magnesium prophylaxis does not interfere with acute triptans, NSAIDs, antiemetics, or CGRP antagonists; these remain available for acute attacks.
Pediatric dosing — 5-9 mg/kg/day elemental, divided into 2-3 doses, as used in the Wang trial.
Menstrual migraine — Daily baseline or perimenstrual escalation as discussed above.

Back to Table of Contents

Combining Magnesium with Riboflavin, CoQ10, and Feverfew

The "3-vitamin/herb" approach to migraine prevention combines magnesium with two or three other Level B/C nutraceuticals. This pattern is widely adopted in headache specialty clinics and increasingly in primary care.

Magnesium 400-600 mg + Riboflavin 400 mg + CoQ10 100-300 mg — The classic "3-stack" used by neurology referral centers. Each component is independently Level B/C; the combination's additive vs. multiplicative effect has not been formally tested in head-to-head trials but is mechanistically rational (magnesium = NMDA/CGRP; riboflavin = mitochondrial electron transport flavin cofactor; CoQ10 = mitochondrial electron transport).
Adding feverfew — The MIG-99 standardized feverfew extract has Level B evidence for migraine prevention through inhibition of platelet serotonin release. Adding 50-100 mg/day of standardized feverfew to the magnesium/riboflavin/CoQ10 stack is a reasonable next step for patients with partial response.
The riboflavin-magnesium synergy — Both supplements target migraine's underlying mitochondrial energy-failure pattern. Riboflavin's effect is also strongest at 8-12 weeks; the loading periods match magnesium's.
Petadolex (butterbur) caveat — Butterbur (Petasites hybridus) was originally Level A but has been downgraded due to hepatotoxicity from unprocessed plant material. Only highly processed, pyrrolizidine-alkaloid-free preparations (Petadolex was one) should ever be used, and many specialists have stopped recommending butterbur altogether.
Combining with prescription preventives — Magnesium does not pharmacokinetically interact with topiramate, valproate, beta-blockers, or CGRP antagonists. It can safely be layered onto prescription prevention to push response in patients with incomplete benefit from a single agent.

See Magnesium, Riboflavin, and Supplements for Migraine for a deeper discussion of the combined-nutraceutical approach.

Back to Table of Contents

Cautions, Side Effects, and Drug Interactions

GI side effects — The dose-limiting side effect. Citrate and oxide are most laxative; glycinate and threonate are best tolerated. Splitting daily total dose into AM + PM improves tolerability.
Chronic kidney disease — Magnesium accumulates in CKD due to impaired renal excretion; supplementation in CKD requires medical supervision.
Pregnancy — Oral magnesium is generally safe in pregnancy and is often used for both pregnancy-related leg cramps and migraine prophylaxis when triptans are avoided. IV magnesium has an established obstetric safety profile.
Heart block — Avoid high doses in second- or third-degree AV block.
Quinolones, tetracyclines, levothyroxine, bisphosphonates — Magnesium chelates these; separate doses by 2-4 hours (4 hours for levothyroxine).
PPIs — Long-term PPI use depletes magnesium; PPI users often benefit from supplementation rather than needing to avoid it.
Diuretics — Loop and thiazide diuretics increase urinary magnesium loss; supplementation often needed in chronic diuretic users.
Pre-surgical disclosure — Magnesium potentiates neuromuscular blockers; disclose any supplementation to your anesthesiologist before surgery.

Note: Persistent or severe headaches, headaches with neurological deficit (weakness, persistent visual loss, slurred speech, severe disorientation), "worst-headache-of-life" presentation, headaches accompanied by fever and neck stiffness, or new-onset headaches in patients over 50 require immediate medical evaluation. Magnesium prophylaxis is for patients with a documented migraine diagnosis under appropriate clinical care, not a substitute for evaluation of new or alarming headaches.

Back to Table of Contents

Key Research Papers

Mauskop A, Varughese J (2012). Why all migraine patients should be treated with magnesium. Journal of Neural Transmission. — PubMed: Mauskop & Varughese 2012
Peikert A, Wilimzig C, Köhne-Volland R (1996). Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia. — PubMed: Peikert 1996
Pfaffenrath V et al. (1996). Magnesium in the prophylaxis of migraine — a double-blind placebo-controlled study. Cephalalgia. — PubMed: Pfaffenrath 1996
Köseoglu E, Talaslioglu A, Gönül AS, Kula M (2008). The effects of magnesium prophylaxis in migraine without aura. Magnesium Research. — PubMed: Köseoglu 2008
Bigal ME, Bordini CA, Tepper SJ, Speciali JG (2002). Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A randomized, double-blind, placebo-controlled study. Cephalalgia. — PubMed: Bigal 2002
Chiu HY, Yeh TH, Huang YC, Chen PY (2016). Effects of intravenous and oral magnesium on reducing migraine: a meta-analysis of randomized controlled trials. Pain Physician. — PubMed: Chiu 2016 meta-analysis
Wang F, Van Den Eeden SK, Ackerson LM, Salk SE, Reince RH, Elin RJ (2003). Oral magnesium oxide prophylaxis of frequent migrainous headache in children: a randomized, double-blind, placebo-controlled trial. Headache. — PubMed: Wang 2003 pediatric
Facchinetti F, Sances G, Borella P, Genazzani AR, Nappi G (1991). Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache. — PubMed: Facchinetti menstrual
Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E (2012). Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults. Neurology. (AAN/AHS Level B guideline) — PubMed: AAN/AHS 2012 guideline
Pringsheim T, Davenport W, Mackie G, et al. (2012). Canadian Headache Society guideline for migraine prophylaxis. Canadian Journal of Neurological Sciences. — PubMed: Canadian guideline 2012
Welch KMA, Ramadan NM (1995). Mitochondria, magnesium and migraine. Journal of the Neurological Sciences. — PubMed: Welch Ramadan mitochondria
Lodi R, Iotti S, Cortelli P, et al. (2001). Deficient energy metabolism is associated with low free magnesium in the brains of patients with migraine and cluster headache. Brain Research Bulletin. — PubMed: Lodi MR spectroscopy
Demirkaya S, Vural O, Dora B, Topcuoglu MA (2001). Efficacy of intravenous magnesium sulfate in the treatment of acute migraine attacks. Headache. — PubMed: Demirkaya IV magnesium
American Headache Society (2021). The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache. — PubMed: AHS 2021 consensus

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents